903 related articles for article (PubMed ID: 21047492)
1. Dronedarone for the treatment of atrial fibrillation and atrial flutter.
Maund E; McKenna C; Sarowar M; Fox D; Stevenson M; Pepper C; Palmer S; Woolacott N
Health Technol Assess; 2010 Oct; 14(Suppl. 2):55-62. PubMed ID: 21047492
[TBL] [Abstract][Full Text] [Related]
2. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
McKenna C; Maund E; Sarowar M; Fox D; Stevenson M; Pepper C; Woolacott N; Palmer S
Pharmacoeconomics; 2012 Jan; 30(1):35-46. PubMed ID: 22136303
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia.
Tesic D; Kostic M; Paunovic D; Jankovic SM
Kardiol Pol; 2015; 73(4):287-95. PubMed ID: 25428811
[TBL] [Abstract][Full Text] [Related]
4. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
Åkerborg Ö; Nilsson J; Bascle S; Lindgren P; Reynolds M
Clin Ther; 2012 Aug; 34(8):1788-802. PubMed ID: 22770643
[TBL] [Abstract][Full Text] [Related]
6. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
Naccarelli GV; Johnston SS; Lin J; Patel PP; Schulman KL
Clin Cardiol; 2010 May; 33(5):270-9. PubMed ID: 20513065
[TBL] [Abstract][Full Text] [Related]
7. Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial.
Reynolds MR; Lin J; Jhaveri M; Mozaffari E; Plich A
Am J Ther; 2014; 21(6):500-8. PubMed ID: 23344106
[TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Valembois L; Audureau E; Takeda A; Jarzebowski W; Belmin J; Lafuente-Lafuente C
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD005049. PubMed ID: 31483500
[TBL] [Abstract][Full Text] [Related]
9. A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Gonzalez MD
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):24S-30S. PubMed ID: 21098416
[TBL] [Abstract][Full Text] [Related]
10. Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.
Wolbrette D; Gonzalez M; Samii S; Banchs J; Penny-Peterson E; Naccarelli G
Vasc Health Risk Manag; 2010 Aug; 6():517-23. PubMed ID: 20730068
[TBL] [Abstract][Full Text] [Related]
11. Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Duray GZ; Schmitt J; Hohnloser SH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):19S-23S. PubMed ID: 20472812
[TBL] [Abstract][Full Text] [Related]
12. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C; Valembois L; Bergmann JF; Belmin J
Cochrane Database Syst Rev; 2015 Mar; (3):CD005049. PubMed ID: 25820938
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Guerra F; Hohnloser SH; Kowey PR; Crijns HJ; Aliot EM; Radzik D; Roy D; Connolly S; Capucci A
Clin Cardiol; 2014 Dec; 37(12):717-24. PubMed ID: 25470298
[TBL] [Abstract][Full Text] [Related]
15. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Freemantle N; Lafuente-Lafuente C; Mitchell S; Eckert L; Reynolds M
Europace; 2011 Mar; 13(3):329-45. PubMed ID: 21227948
[TBL] [Abstract][Full Text] [Related]
16. Dronedarone: a promising alternative for the management of atrial fibrillation.
Yalta K; Turgut OO; Yilmaz MB; Yilmaz A; Tandogan I
Cardiovasc Drugs Ther; 2009 Oct; 23(5):385-93. PubMed ID: 19669399
[TBL] [Abstract][Full Text] [Related]
17. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH;
Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.
Nilsson J; Åkerborg Ö; Bégo-Le Bagousse G; Rosenquist M; Lindgren P
Eur J Health Econ; 2013 Jun; 14(3):481-93. PubMed ID: 22552487
[TBL] [Abstract][Full Text] [Related]
19. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation.
Rodgers M; McKenna C; Palmer S; Chambers D; Van Hout S; Golder S; Pepper C; Todd D; Woolacott N
Health Technol Assess; 2008 Nov; 12(34):iii-iv, xi-xiii, 1-198. PubMed ID: 19036232
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dronedarone: a review of randomized trials.
Christiansen CB; Torp-Pedersen C; Køber L
Expert Opin Drug Saf; 2010 Jan; 9(1):189-99. PubMed ID: 20001756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
